FY2029 Earnings Estimate for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Equities researchers at HC Wainwright cut their FY2029 earnings estimates for shares of PolyPid in a research note issued to investors on Thursday, May 14th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of $1.74 per share for the year, down from their previous estimate of $1.90. HC Wainwright currently has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.34) per share. HC Wainwright also issued estimates for PolyPid’s FY2030 earnings at $3.77 EPS.

Several other research firms have also commented on PYPD. Weiss Ratings lowered shares of PolyPid from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Wall Street Zen upgraded shares of PolyPid from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, PolyPid has an average rating of “Moderate Buy” and an average price target of $12.25.

PolyPid Stock Performance

Shares of NASDAQ PYPD opened at $4.76 on Monday. The firm has a market capitalization of $90.82 million, a P/E ratio of -2.49 and a beta of 1.41. PolyPid has a one year low of $2.44 and a one year high of $5.12. The company’s fifty day moving average is $4.41 and its two-hundred day moving average is $4.26.

PolyPid (NASDAQ:PYPD) last issued its earnings results on Wednesday, May 13th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.12.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its stake in PolyPid by 56.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after purchasing an additional 3,500 shares during the last quarter. HighTower Advisors LLC acquired a new position in PolyPid in the 4th quarter valued at about $44,000. Jane Street Group LLC acquired a new position in PolyPid in the 4th quarter valued at about $66,000. Renaissance Technologies LLC acquired a new position in PolyPid in the 1st quarter valued at about $81,000. Finally, XTX Topco Ltd raised its stake in PolyPid by 50.0% in the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after purchasing an additional 10,888 shares during the last quarter. Institutional investors and hedge funds own 26.47% of the company’s stock.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.